reports
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on ...
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will be presenting late-breaking Phase 2 clinical data on its antiviral influenza candidate, CD388, during ID Week 2025, taking place October 19-22, 2025, in Atlanta, GA. Presentation details are summarized below: Presentation Title: A Randomized, Placebo-controlled Trial to...
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025
Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025 SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have a late-breaking presentation at the European Scientific Working Group on Influenza (ESWI)’s 10th Influenza Conference taking place October 20-23, 2025 in Valencia, Spain. Presentation details are summarized below: Late-Breaking Abstract Title: Translational efficacy of CD388, a novel Dru...
Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation...
Cidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention Breakthrough Therapy designation comes in addition to previously awarded Fast Track designation SAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for CD388 for prevention of influenza A and B in adults and adolescent...
Cidara Therapeutics Announces BARDA Award to Support Expanded Manufact...
Cidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it has received an award valued up to $339M from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Departm...
Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCH...
Cidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations - Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeu...
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan fo...
Cidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza - Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if successful, may be sufficient for BLA approval - Phase 3 study population expanded to include adults over 65 years of age in addition to subjects with high-risk co-morbidities and immune compromised status SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Cidar...
Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE ...
Cidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting - Efficacy and safety results from successful NAVIGATE Phase 2b trial of CD388 for prevention of influenza illness featured in late-breaking presentation - Preclinical data demonstrating potential efficacy of CD388 to prevent H5N1 infection featured in oral presentation SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop...
Cidara Therapeutics to Participate in September Investor Conferences
Cidara Therapeutics to Participate in September Investor Conferences SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below September investor conferences. Details are as follows: Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 8, 2025Time: 4:00 PM ETFormat: Corporate Presentation Event: Morgan Stanley 23rd Annual Global Healthcare Conferen...
Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical ...
Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have two oral presentations, one of which is late-breaking, during the International Society for Respiratory Viruses (ISRV) 8th AntiViral Group (AVG) Meeting and 3rd International Meeting on Respiratory Pathogens (IMRP). The conferenc...
Cidara Therapeutics Provides Corporate Update and Reports Second Quart...
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results Phase 2b NAVIGATE clinical trial evaluating CD388 for the prevention of seasonal influenza met primary and all secondary efficacy endpoints for all dose groupsEnd of Phase 2 meeting request submitted to the U.S. Food and Drug Administration (FDA)Closed upsized public offering for gross proceeds of $402.5 million; significantly strengthened balance sheet to conduct planned Phase 3 program for CD388Added to Russell 2000® and Russell 3000® IndexesConference call and webcast today at 5:00 PM Eastern ...
Cidara Therapeutics to Report Second Quarter 2025 Financial Results an...
Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025 SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its second quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, August 7, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss t...
- Jonathan Moreland
PSEC PROSPECT CAPITAL CORPORATION
ORCL ORACLE CORPORATION
NG. NOVAGOLD RESOURCES INC.
MERC MERCER INTERNATIONAL INC.
HELE HELEN OF TROY LIMITED
WELL WELLTOWER INC.
CEVA CEVA INC.
CDTX CIDARA THERAPEUTICS
CIVB CIVISTA BANCSHARES
NXRT NEXPOINT RESIDENTIAL TRUST INC.
DYN DYNEGY INC.
GIII G-III APPAREL GROUP LTD.
PETS PETMED EXPRESS INC.
THO THOR INDUSTRIES INC.
GRF EAGLE CAPITAL GROWTH FUND INC
CRSP CRISPR THERAPEUTICS AG
CRVL CORVEL CORP.
CLRB CELLECTAR BIOSCIENCES
ELTP ELITE PHARMACEUTICALS INC
COGT COGINT
BWB INC.
DOMO BRIDGEWATER BANCSHARES
FGBI DOMO INCORPORATED
PVH FIRST GUARANTY BANCSHARES
GRX PHILLIPS-VAN HEUSEN CORPORATION
INLX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
FRHC INTELLINETICS
CMTV INC.
RZLT FREEDOM HOLDING CORP
KYMR COMMUNITY BANCORP INC. VT
BTBT REZOLUTE
TERN INC.
CTO KYMERA THERAPEUTICS
VERA BIT DIGITAL (N SHARES)
IMRX TERNS PHARMACEUTICALS
BRCC CONSOLIDATED-TOMOKA LAND CO
BPRN VERA THERAPEUTICS INC
PMNT IMMUNEERING CORP
NYC BRC INC
ACTU BANK OF PRINCETON
MBRX PERFECT MOMENT LTD.
LION NEW YORK CITY REIT
THAR INC.
FGEN ACTUATE THERAPEUTICS INC.
CCIF MOLECULIN BIOTECH INC.
BMNR LIONSGATE STUDIOS CORP
NEGG THARIMMUNE INC.
FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
BITMINE IMMERSION TECHNOLOGIES INC.
NEWEGG COMMERCE INC.
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
PSEC PROSPECT CAPITAL CORPORATION
ORCL ORACLE CORPORATION
NG. NOVAGOLD RESOURCES INC.
MERC MERCER INTERNATIONAL INC.
WELL WELLTOWER INC.
CEVA CEVA INC.
CDTX CIDARA THERAPEUTICS
PZG PARAMOUNT GOLD NEVADA CORP.
NXRT NEXPOINT RESIDENTIAL TRUST INC.
GIII G-III APPAREL GROUP LTD.
OXM OXFORD INDUSTRIES INC.
THO THOR INDUSTRIES INC.
GRF EAGLE CAPITAL GROWTH FUND INC
CRVL CORVEL CORP.
SVRA SAVARA
CLRB CELLECTAR BIOSCIENCES
ELTP ELITE PHARMACEUTICALS INC
RSSS RESEARCH SOLUTIONS
BWB BRIDGEWATER BANCSHARES
DOMO DOMO INCORPORATED
FGBI FIRST GUARANTY BANCSHARES
PVH PHILLIPS-VAN HEUSEN CORPORATION
AMPY AMPLIFY ENERGY
INLX INTELLINETICS
FRHC INC.
CMTV FREEDOM HOLDING CORP
RZLT COMMUNITY BANCORP INC. VT
KYMR REZOLUTE
WSC INC.
BTBT KYMERA THERAPEUTICS
TERN WILLSCOT MOBILE MINI HOLDINGS CORP
NUVB BIT DIGITAL (N SHARES)
CTO TERNS PHARMACEUTICALS
VERA NUVATION BIO INC (A)
IMRX CONSOLIDATED-TOMOKA LAND CO
XLO VERA THERAPEUTICS INC
SSBK IMMUNEERING CORP
PMNT XILIO THERAPEUTICS INC
NYC SOUTHERN STATES BANCSHARES INC
ACTU PERFECT MOMENT LTD.
SUNS NEW YORK CITY REIT
MBRX INC.
LION ACTUATE THERAPEUTICS INC.
HYMC SUNRISE REALTY TRUST
THAR MOLECULIN BIOTECH INC.
FGEN LIONSGATE STUDIOS CORP
CCIF HYCROFT MINING HOLDING CORPORATION
BTCS THARIMMUNE INC.
FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
TOUCHIT TECHNOLOGIES
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
HPP HUDSON PACIFIC PROPERTIES INC.
PSEC PROSPECT CAPITAL CORPORATION
NG. NOVAGOLD RESOURCES INC.
WELL WELLTOWER INC.
CDXS CODEXIS
CDTX CIDARA THERAPEUTICS
AMPH AMPHASTAR PHARMACEUTICALS INC
PZG PARAMOUNT GOLD NEVADA CORP.
NXRT NEXPOINT RESIDENTIAL TRUST INC.
GIII G-III APPAREL GROUP LTD.
OXM OXFORD INDUSTRIES INC.
THO THOR INDUSTRIES INC.
GRF EAGLE CAPITAL GROWTH FUND INC
MLP MAUI LAND & PINEAPPLE CO. INC.
SVRA SAVARA
CLRB CELLECTAR BIOSCIENCES
STKL SUNOPTA
RSSS INC.
BWB RESEARCH SOLUTIONS
DOMO BRIDGEWATER BANCSHARES
SONO DOMO INCORPORATED
A2JHXF SONOS
FGBI CEVA LOGISTICS AG
PVH FIRST GUARANTY BANCSHARES
AMPY PHILLIPS-VAN HEUSEN CORPORATION
INLX AMPLIFY ENERGY
FRHC INTELLINETICS
RZLT INC.
KYMR FREEDOM HOLDING CORP
WSC REZOLUTE
BTBT INC.
TERN KYMERA THERAPEUTICS
NUVB WILLSCOT MOBILE MINI HOLDINGS CORP
CTO BIT DIGITAL (N SHARES)
VERA TERNS PHARMACEUTICALS
IMRX NUVATION BIO INC (A)
XLO CONSOLIDATED-TOMOKA LAND CO
SSBK VERA THERAPEUTICS INC
NCDL IMMUNEERING CORP
PMNT XILIO THERAPEUTICS INC
NYC SOUTHERN STATES BANCSHARES INC
ACTU NUVEEN CHURCHILL DIRECT LENDING CORP
SUNS PERFECT MOMENT LTD.
MBRX NEW YORK CITY REIT
HYMC INC.
THAR ACTUATE THERAPEUTICS INC.
FGEN SUNRISE REALTY TRUST
CCIF MOLECULIN BIOTECH INC.
HYCROFT MINING HOLDING CORPORATION
THARIMMUNE INC.
FIBROGEN INC.
CARLYLE CREDIT INCOME FUND
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rul...
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted non-qualified stock option awards and restricted stock units (RSUs) for an aggregate of 12,100 shares of its common stock to two new employees, pursuant to the Cidara Therapeutics, ...
- Jonathan Moreland
CDTX CIDARA THERAPEUTICS
GRF EAGLE CAPITAL GROWTH FUND INC
PVH PHILLIPS-VAN HEUSEN CORPORATION
TERN TERNS PHARMACEUTICALS
IMRX IMMUNEERING CORP
SONM SONIM TECHNOLOGIES INC
ACTU ACTUATE THERAPEUTICS INC.
DSM DREYFUS STRATEGIC MUNICIPAL BOND FUND
LION INC.
CCIF LIONSGATE STUDIOS CORP
CARLYLE CREDIT INCOME FUND
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russe...
Cidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its addition to the Russell 2000® and Russell 3000® Indexes. The Russell 3000 Index encompasses the 3,000 largest U.S. companies by market capitalization, representing approximately 98% of the investable U.S. equity market. The Russell 2000 Index is a subset of the Russell 3000, m...
Cidara Announces Closing of Upsized Public Offering and Full Exercise ...
Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the closing of its underwritten public offering of 9,147,727 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,193,181 shares, at a price to the public of $44.00 per sh...
Cidara Announces Pricing of Upsized Public Offering of Common Stock
Cidara Announces Pricing of Upsized Public Offering of Common Stock SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced the pricing of an underwritten public offering of 7,954,546 shares of its common stock at a price to the public of $44.00 per share. All of the shares are to be sold by Cidara. The gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and offering ex...
Cidara Announces Proposed Public Offering of Common Stock
Cidara Announces Proposed Public Offering of Common Stock SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250.0 million of shares of its common stock. All of the shares are being offered by Cidara. In connection with the proposed offering, Cidara expects to grant the underwriters a 30-day option to...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.